SCHEMBL4823700

SCHEMBL4823700

CC1=C(C)c2ccc(-c3ccccc3)cc2[CH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.44
APAF1 O14727 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
XBP1 P17861 1/20 0.44
PTBP1 P26599 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
GALK1 P51570 1/20 0.44
BLM P54132 1/20 0.44
SMAD3 P84022 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717056 0.79 MEN1 (0.48) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL27862666 0.77 MEN1 (0.47) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL6228874 0.77 MEN1 (0.41) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL3773666 0.74 L3MBTL1 (0.41) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL2051706 0.74 MEN1 (0.48) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL28939189 0.72 MEN1 (0.42) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL61525 0.72 MEN1 (0.39) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL22923706 0.71 ESR2 (0.46) L3MBTL1MEN1APAF1NPC1LMNA
SCHEMBL27272943 0.70 MEN1 (0.38) L3MBTL1MEN1LMNAMAPTTHRB
SCHEMBL27709736 0.70 MEN1 (0.38) L3MBTL1MEN1LMNAMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337536-B1 CATIONIC GROUP-3 CATALYST SYSTEM EXXONMOBIL CHEM PATENTS INC (US) 2012-09-12 EP disclosed
US-7390861-B2 Cationic group-3 catalyst system EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-06-24 US disclosed
US-20040033891-A1 Cationic group-3 catalyst system EXXONMOBIL CHEMICAL PATENTS INC. 2004-02-19 US disclosed
EP-1337536-A1 CATIONIC GROUP-3 CATALYST SYSTEM ExxonMobil Chemical Patents Inc. (US) 2003-08-27 EP disclosed
WO-2002032909-A1 CATIONIC GROUP-3 CATALYST SYSTEM EXXONMOBIL CHEMICAL PATENTS INC. (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033891-A1 Cationic group-3 catalyst system COG3, ORC3, LIG3 L3MBTL1 489/4885MEN1 1242/4885APAF1 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.